Sitagliptin With Pembro in RCC and Melanoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped responding to prior PD-1 or PD-L1 immunotherapy. The study has two parts. In the first part, small groups of participants will receive different doses of sitagliptin along with a fixed dose of pembrolizumab. This helps researchers find the highest dose of sitagliptin that can be given safely. In the second part, more participants will receive the safest dose to see how well the drug combination works against their cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony, nieoperacyjny, rozsiany czerniak (z wyłączeniem czerniaka błon śluzowych i oka) lub rak nerki (głównie typ z komórkami jasnymi), który postępował mimo leczenia immunoterapią (leki anty-PD-1/PD-L1).
- •Stan ogólny pacjenta pozwala na uczestnictwo w badaniu (skala ECOG 0-2).
- •Widoczne w badaniach obrazowych zmiany nowotworowe spełniające określone kryteria wielkości i możliwości pomiaru.
- •Pacjent ma 18 lat lub więcej.
- •Pacjent rozumie zasady badania i wyraża świadomą zgodę na udział.
- •Dolegliwości wynikające z wcześniejszych zabiegów lub terapii ustąpiły do poziomu uznawanego za bezpieczny.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- July 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Iowa
Iowa City, United States
Trial contact
Fernando Maciel Barbosa, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.